NCT03526679 2025-12-05
LEADER
National Taiwan University Hospital
Phase 1/2 Completed
Clinical Trials
8 trialsNCT01126736 2023-06-22
Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer
Eisai Inc.
Phase 1/2 Completed
NCT03245450 2022-06-28
Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT02513472 2022-05-05
ENHANCE-1
Eisai Inc.
Phase 1/2 Completed
NCT01554371 2021-02-03
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
University of California, San Francisco
Phase 1/2 Completed
NCT01323530 2021-01-11
A Confirmation Study of Eribulin in Combination With Capecitabine
Eisai Inc.
Phase 1/2 Completed
NCT01596751 2020-07-17
Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
University of California, San Francisco
Phase 1/2 Completed
NCT02723877 2019-03-22
PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)
PIQUR Therapeutics AG
Phase 1/2 Completed